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 Abstract 20 
Study question: What is the chance of a live birth following one or more linked complete cycles of 21 
IVF (including ICSI)? 22 
Summary answer: The chance of a live birth after three complete cycles of IVF was 42.3% for 23 
treatment commencing from 1999 to 2007. 24 
What is known already:  IVF success has generally been reported on the basis of live birth rates after 25 
a single episode of treatment resulting in the transfer of a fresh embryo.  This fails to capture the 26 
real chance of having a baby after a number of complete cycles – each involving the replacement of 27 
fresh as well as frozen-thawed embryos. 28 
Study design, size and duration: 29 
Population based observational cohort study of 178,898 women between 1992 and 2007. 30 
Participants/materials, setting, methods: 31 
Participants included all women who commenced IVF treatment at a licenced clinic in the UK as 32 
recorded in the Human Fertilisation and Embryology Authority national database.  Exclusion criteria 33 
included women whose treatment involved donor insemination, egg donation, surrogacy, and the 34 
transfer of more than three embryos.  Cumulative rates of live birth, term (>37 weeks) singleton live 35 
birth, and multiple pregnancy were estimated for two time-periods, 1992-1998 and 1999-2007. 36 
Conservative estimates assumed that women who did not return for IVF would not have the 37 
outcome of interest while optimal estimates assumed that these women would have similar 38 
outcome rates to those who continued IVF.  39 
Main results and the role of chance: 40 
A total of 71,551 women commenced IVF treatment during 1992–1998 and an additional 107,347 41 
during 1999–2007. After the third complete IVF cycle (defined as three fresh IVF treatments - 42 
including replacement of any surplus frozen-thawed embryos), the conservative CLBR in women who 43 
 commenced IVF during 1992-1998 was 30.8% increasing to 42.3% during 1999-2007.  The optimal 44 
CLBRs were 44.6% and 57.1% respectively. After eight complete cycles the optimal CLBR was 82.4% 45 
in the latter time period.  The conservative rate for multiple pregnancy per pregnant woman fell 46 
from 31.9% during the earlier time period to 26.2% during the latter.   47 
Limitations and reason for caution: 48 
Linkage of all IVF treatments to individual women was conducted.  However, it was not possible to 49 
identify with certainty in all cases the episode of ovarian stimulation which generated some of the 50 
frozen embryos.  Cumulative live birth rates could not be calculated for women who started 51 
treatment beyond 2007 as follow up data were incomplete in some of them. Following a change in 52 
legislation in 2008, linked data were only made available for research in women who gave formal 53 
consent for this purpose. 54 
Wider implications of the findings:  55 
Our results demonstrate, at a national level, the chances of livebirth in couples undergoing a number 56 
of complete (fresh and frozen) IVF cycles. They reflect improvements in reproductive technology and 57 
a more conservative embryo transfer policy.  Although most couples in the UK still do not receive 58 
three complete IVF cycles; assuming no barriers to continuation of IVF treatment, around 83% of 59 
women receiving IVF would achieve a live birth by the eighth complete cycle, similar to the natural 60 
live birth rate in a non-contraception practising population.  Our results support the call from NICE to 61 
develop consistent IVF policies based on three complete cycles. 62 
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The views expressed here are those of the authors and not necessarily those of the Chief Scientist 65 
Office.  SB reports grants from Chief Scientist Office Scotland during the conduct of the study. His 66 
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 Introduction 73 
Globally, the estimated prevalence of infertility is around 9% (Boivin et al. 2007), whilst in the UK, 74 
around one in six couples experience problems conceiving (Oakley et al. 2008). Most couples with 75 
prolonged unresolved infertility eventually proceed to in vitro fertilisation (defined here as IVF or 76 
ICSI) and the number of women treated in the United Kingdom (UK) has increased annually from 77 
6184 in 1991 to 49636 in 2013 (Human Fertilisation and Embryology Authority 2008a, Human 78 
Fertilisation and Embryology Authority 2012, Human Fertilisation and Embryology Authority 2013a). 79 
Worldwide, by the end of 2013 over five million people were estimated to have been born as a 80 
result of IVF (Adamson et al. 2012), with the UK accounting for over 4% of this total (Human 81 
Fertilisation and Embryology Authority 2014). 82 
IVF success has generally been calculated and reported on the basis of live birth rates per treatment 83 
attempt involving either an intended fresh or frozen-thawed embryo replacement (Vrtacnik et al. 84 
2014, Elizur et al. 2006, Ke et al. 2013, Sharma et al. 2002, Abuzeid et al. 2014).   85 
The continued improvement in reproductive technology has seen an increase in the number of 86 
frozen-thawed embryo transfers (De Mouzon et al. 2010) and their associated pregnancy rates 87 
(Roque et al. 2013).  This, combined with an emphasis on reducing multiple pregnancies and 88 
increasing single embryo transfers ;NatioŶal CollaďoƌatiŶg CeŶtƌe foƌ WoŵeŶ͛s aŶd ChildƌeŶ͛s Health 89 
2013), means that outcomes per fresh embryo transfer are no longer meaningful to patients and 90 
clinicians who want to know their chance of a live birth over an entire IVF programme (Maheshwari 91 
et al. 2015).  The most appropriate way of reporting this is to estimate the cumulative chances of 92 
success per woman after a number of complete cycles, - defined as all fresh and frozen-thawed 93 
embryo transfer attempts resulting from one episode of ovarian stimulation (Moragianni and 94 
Penzias 2010).  The complete cycle definition allows realisation of the total reproductive potential of 95 
each single fresh cycle including the contribution of all subsequent frozen-thawed embryo transfers 96 
derived from it (Jones et al. 1997, Stern et al. 2012).  Cumulative live birth rates (CLBRs) following IVF 97 
 have been reported mainly at a sub-national level (Vrtacnik et al. 2014, Ke et al. 2013, Malizia et al. 98 
2009, Elizur et al. 2006). Although they have been reported at the national level in the United States 99 
(Stern et al. 2013, Luke et al, 2012) and Australia and New Zealand (Macaldowie et al. 2013) not all 100 
the reports have been able to generate figures for cumulative live birth after several complete IVF 101 
cycles.  Until now, no studies have reported such rates for the UK (Johnson and Franklin 2013). Given 102 
the national shift towards elective single embryo transfer and freezing of surplus embryos (National 103 
CollaďoƌatiŶg CeŶtƌe foƌ WoŵeŶ͛s aŶd ChildƌeŶ͛s Health ϮϬϭϯ, The Multiple Biƌths FouŶdatioŶ, 104 
2015), CLBRs are increasingly proving to be the currency of IVF. As such, it is important to determine 105 
what their values are for couples embarking on IVF, and how they have changed over time with 106 
increasing uptake of embryo freezing. Additionally, since multiple pregnancy is associated with 107 
increased maternal and perinatal morbidity and mortality (Mansour et al. 2014, Sunderam et al. 108 
2014), it is useful to explore whether changes in practice have resulted in reducing cumulative 109 
multiple pregnancy rates and increasing the numbers of healthy babies – i.e. rates of term singleton 110 
live births (Min et al. 2004). 111 
The Human Fertilisation and Embryology Authority (HFEA) has collected data on all licensed fertility 112 
treatments in the UK since 1992.  An anonymised HFEA database is freely available for research 113 
purposes and has been utilised in several studies (Human Fertilisation and Embryology Authority 114 
2013b, Sunkara et al. 2011, Nelson and Lawlor 2011, Bhattacharya et al. 2013,). However, as it only 115 
contains data at the individual (fresh or frozen) IVF treatment level there is no way of linking one or 116 
more complete IVF cycles to an individual woman in order to estimate CLBRs. However, a more 117 
detailed version of the HFEA database is available for research purposes under strict conditions 118 
which links all IVF treatments to complete cycles and to individual women (Williams et al 2013) and 119 
allows estimation of cumulative live birth rates.  A population-based cohort study was conducted to 120 
investigate the cumulative live birth rate per woman following one or more linked complete cycles 121 
of IVF.  This was repeated for outcomes of term singleton live birth per woman and multiple 122 
pregnancy per pregnant woman following IVF.  We also aimed to explore whether the cumulative 123 
 live birth rate increased over time and the characteristics of women accessing IVF as well as their 124 
patterns of treatment over time. 125 
 126 
Methods 127 
Database access 128 
Access to the detailed HFEA database was subject to approval from the North of Scotland Research 129 
Ethics Committee, the Confidentiality Advisory Group, and the HFEA Register Research Panel. 130 
Consent for IVF patient data to ďe used iŶ ƌeseaƌĐh ĐhaŶged fƌoŵ ͚pƌesuŵed͛ to ͚ƌeƋuiƌed͛ iŶ 131 
October 2009.  Therefore, from October 2009, only details relating to those patients who provided 132 
explicit consent for their data to be used in research were available.  133 
AŶoŶǇŵised ͞peƌ ǁoŵaŶ͟ data were transferred to the University of Aberdeen where they were 134 
stored and analysed using the dedicated secure Data Safe Haven (DaSH) University of Aberdeen 135 
server with access restricted to approved researchers. 136 
Study population 137 
Records of all fresh and frozen-thawed IVF (including ICSI) treatments in women who embarked on 138 
IVF in the UK between January 1992 and December 2011 were extracted.  Since the treatment 139 
information were linked to the individual we were able to identify and code complete cycles of IVF 140 
for each woman by combining her fresh treatment with its associated frozen-thawed treatments (so 141 
that the total reproductive potential could be determined).  For clarity, our definition of a complete 142 
cycle is all fresh and frozen-thawed embryo transfer attempts resulting from one episode of ovarian 143 
stimulation (National Collaborating Centre foƌ WoŵeŶ͛s aŶd ChildƌeŶ͛s Health ϮϬϭϯͿ. The following 144 
exclusion criteria were applied: 145 
 1. Women having any element of treatment involving donor insemination, egg donation, and 146 
surrogacy.  147 
2. Women who had treatment where the express purpose was storage of eggs or embryos.   148 
3. Women aged less than 18 or over 50 in their first treatment.   149 
4. Women with more than three embryos transferred in any treatment since this was a very 150 
rare occurrence in the UK (20 over the whole study period). 151 
5. Women whose first treatment in the database was a thawed embryo transfer since this 152 
indicated previous unrecorded treatment. 153 
6. Women who received their first treatment in 2008 and 2009 were excluded so that a 154 
minimum of two years exposure time could be achieved for women commencing treatment 155 
in 2007.   Tǁo Ǉeaƌs ǁas ĐhoseŶ siŶĐe this Đaptuƌed oǀeƌ 9Ϭ% of ǁoŵeŶ͛s total eǆposuƌe to 156 
treatment in the database. The years where the opt-in policy was in action (2010 to 2011) 157 
were excluded since their inclusion would have led to falsely higher discontinuation rates 158 
due to women opting not to disclose their treatment information in later treatments. 159 
Baseline characteristics 160 
Baseline characteristics of women at the beginning of their first complete cycle included age (<31, 161 
31-35, 36-40, and >40 years), type of infertility (categorised as single diagnosis of tubal, 162 
endometriosis, anovulation, male factor, or unexplained, or as any multiple diagnosis), and year.   163 
Outcomes 164 
Since the complete cycle information was linked to individual women, this enabled us to identify the 165 
first live birth and first multiple pregnancy occurrences per woman over multiple complete cycles.  166 
Once a woman achieved her first live born baby from IVF they did not contribute any further to the 167 
cumulative rates.  Outcomes were cumulative live birth rate per woman (CLBR), cumulative term 168 
singleton live birth rate per woman, and cumulative multiple pregnancy rate per pregnant woman.  169 
 Multiple pregnancy was defined as an occurrence of: more than one foetal sac each with foetal 170 
pulsation on scan; or one foetal sac but more than one birth outcome.  171 
Statistical analysis 172 
Descriptive statistics were calculated for patient and treatment characteristics at the first fresh IVF 173 
treatment.  The median (interquartile range (IQR)) number of treatments per patient, median 174 
follow-up time and the most frequent fresh and frozen-thawed treatment patterns per patient were 175 
calculated. The live birth rate at the first fresh IVF treatment was calculated by year.  These results 176 
were used to inform the development of separate time periods over which the CLBRs were 177 
calculated.  This would enable investigation of the improvement in cumulative rates over time.  178 
Three different live birth rates were estimated: 179 
Live birth rate and multiple pregnancy rate (per complete cycle) 180 
The live birth rate per complete cycle was calculated by dividing the number of women in each 181 
complete cycle who had their first live birth by the total number of women who attempted that 182 
complete cycle.  The multiple pregnancy rate per complete cycle was calculated by dividing the 183 
number of women in each complete cycle who had their first multiple pregnancy event by the 184 
number of women who had a pregnancy in that complete cycle. 185 
Conservative CLBR 186 
This assumes that none of the women who discontinued treatment would have had a live birth.  At 187 
each successive complete cycle the total number of women who had their first treatment dependent 188 
live birth up to and including it were divided by the total number of women who ever attempted IVF.  189 
Any further live births occurring in subsequent cycles were not included in this analysis.  The 95% 190 
confidence intervals were calculated using standard errors from the binomial distribution. 191 
Optimal CLBR 192 
 This assumes that women who discontinued treatment would have had the same chance of a live 193 
birth or a multiple pregnancy as those who continued.  The Kaplan-Meier estimate was used to 194 
calculate these rates and pointwise estimates of the 95% confidence intervals were obtained.  195 
Cumulative rates were calculated by different age group and type of infertility values.  This utilised 196 
the linked data by using the values of these characteristics of the woman at the start of her first 197 
complete cycle.  For CLBR, all complete cycles were included up to either the end of follow-up or the 198 
first live birth occurrence, whichever came first. 199 
The CLBR was only calculated for complete cycles where the number of women attempting that 200 
complete cycle was greater than 100.  The above analyses were repeated for the outcome of term 201 
singleton live birth.  The log-rank test was used to compare the optimal CLBRs between the two time 202 
periods and between age and type of infertility within each time period.  The conservative 203 
cumulative multiple pregnancy rate per pregnant woman was calculated by dividing the number of 204 
women in each complete cycle who had their first multiple pregnancy event by the number of 205 
women who got pregnant up until that complete cycle. 206 
Ethical approval 207 
Ethical approval was obtained by the North of Scotland Research Ethics Committee (12/NS/0119).   208 
 209 
Results 210 
A total of 253,417 women underwent 464,333 autologous complete cycles of IVF in the UK from 211 
1992 to 2011.  After exclusions these figures reduced to 218,591 women (438,454 complete cycles) 212 
(see Figure 1).  The live birth rate resulting from the first complete cycle of IVF increased from 16.1% 213 
in 1992 to 31.2% in 2007 (see Figure S1). From 1992 to 1998 the rates slowly increased to 23.1% 214 
before rising to 26.1% in 1999 where they remained steady until 2006 (29.7%).  Based on the 215 
 stability of annual success rates for the first complete cycle, the CLBR was calculated for women who 216 
commenced IVF from 1999 to 2007.  This was to minimize heterogeneity caused by changes in 217 
clinical practice over time.  To assess whether the CLBR improved over time, the CLBR was also 218 
calculated for the earlier time period of 1992 to 1998 (period 1) and compared to the CLBR for 1999 219 
to 2007 (period 2).A total of 71,551 women commenced IVF during period 1 and 107,347 during 220 
period 2 (see Figure 1). Table 1 shows couple and treatment characteristics at the start of the first 221 
complete cycle by time period.  The proportion of women over the age of 35 who received IVF 222 
increased over time from 31.7% during period 1 to 39.6% during period 2.  Unexplained infertility, 223 
the most frequent diagnosis during period 1 (43.8%) slipped to second place during the second 224 
period (27.2%) behind male factor (31.1%).  In the first fresh treatment, the proportion of triple 225 
embryo transfers decreased from 38.8% in period 1 to 8.4% in period 2 (Table 2).  However, the 226 
proportion of single embryo transfers remained the same (~8%) meaning that there were more 227 
double embryo transfers in period 2 (69.4%) than in period 1 (32.9%). The median (IQR) number of 228 
complete cycles was 1 (1, 2) in both time periods. The median (IQR) time from the start of the first 229 
complete cycle to the last fresh or frozen-thawed treatment in the last complete cycle (excluding 230 
women who only had one complete cycle with no frozen-thawed embryo transfer attempts) was 231 
lower in period 2 compared to period 1 (365 (185, 701) versus 314 (165, 609) days; p<0.001).  232 
Treatment patterns  233 
The most frequent treatment patterns were the same in both periods: one fresh treatment (period 1 234 
48.4% versus period 2 51.4%), two consecutive fresh treatments (21.8% versus 21.9%), three 235 
consecutive fresh treatments (9.4% versus 8.5%), and one fresh treatment followed by one frozen-236 
thawed treatment (4.2% versus 4.3%). 237 
Cumulative live birth rates 238 
 The conservative (Figure 2A) and optimal (Figure 2B) CLBRs per woman after the third complete 239 
cycle for patients who commenced IVF from 1992 to 1998 were 30.8% and 44.6% respectively, 240 
increasing to 42.3% and 57.1% from 1999 to 2007 (see Table 3). The respective rates for term 241 
singleton live birth were 17.4% and 27.6% for 1992 to 1998 and 25.6% and 38.5% for 1999 to 2007 242 
(Table S1).  There was a highly significant difference between optimal cumulative live birth rates 243 
across the two time periods (p<0.001).  After eight complete cycles the optimal CLBR was 82.4% in 244 
the latter time period.  The conditional live birth rates per complete cycle tended to show a minimal 245 
decline with each successive complete cycle.   246 
For those patients who did not achieve a live birth following their fresh embryo transfer attempt in 247 
their first complete cycle but who went on to have at least one frozen embryo transfer attempt, the 248 
conditional cumulative live birth rate after three frozen embryo transfer attempts was 33.7% in 249 
period 1 and 41.0% in period 2. 250 
Age group 251 
By age group, the CLBRs per women were higher in period 2 than period 1.  After the third complete 252 
cycle, for those aged <31 at their first complete cycle the conservative CLBRs were 38.6% versus 253 
52.4% in periods 1 and 2 respectively; ages 31-35 (34.6% versus 50.3%), ages 36-40 (22.1% versus 254 
33.9%), ages >40 (5.9% versus 9.8%).  The corresponding optimal CLBRs were 54.1% versus 67.9%, 255 
47.7% versus 64.2%, 33.3% versus 47.0% and 11.4% versus 17.3% respectively. In each time period 256 
the optimal CLBRs were significantly different across the age groups (p<0.001). 257 
Type of infertility  258 
The CLBRs for type of infertility were not calculated for Period 1 as the number of events in some 259 
groups were too small.  In Period 2, couples with a single diagnosis of male factor infertility at their 260 
first complete cycle had the highest CLBR of all types at 45.8% for the conservative estimate and 261 
59.8% for the optimal estimate after the third complete cycle.  This was followed closely by 262 
 endometriosis (44.8% conservative, 57.5% optimal), unexplained infertility (42.2% conservative, 263 
56.2% optimal), tubal infertility (39.5% conservative, 54.6% optimal), and anovulation (39.4% 264 
conservative, 57.6% optimal).  The CLBR for couples with more than one type of infertility was 265 
similar to that for couples with single types of infertility (40.1% conservative, 55.5% optimal). There 266 
was a significant difference between the optimal CLBRs across the types of infertility in the second 267 
period (p<0.001). 268 
Multiple pregnancy rates by time period 269 
By time period, 7495 (30.9%) of 24296 pregnancies during 1992 to 1997 were multiple pregnancies 270 
of which 6368 (85.0%) resulted in a multiple live birth.  For IVF commencing during 1998 to 2007, 271 
13702 (24.8%) of 55270 pregnancies were multiple pregnancies of which 11767 (85.9%) led to a 272 
multiple live birth.  The multiple pregnancy rate per pregnant woman after the first complete cycle 273 
was 31.9% for those that commenced during period 1 and decreased to 26.2% during period 2.  274 
Cumulatively, the multiple pregnancy rates did not increase i.e. they remained the same as the rate 275 
in the first complete cycle for each period. 276 
Discontinuation 277 
The discontinuation rates after each complete cycle were very similar for the two time periods. Of 278 
those women whose first complete cycle did not result in a live birth 42.7% did not return for a 279 
second complete cycle over the following two years in period 1 versus 39.5% in period 2 (Figure S2). 280 
The withdrawal rate per complete cycle increased until complete cycle four and then remained 281 
reasonably steady. 282 
 283 
Discussion 284 
Statement of principal findings 285 
 In this study, national UK cumulative birth outcomes following one or more IVF complete cycles 286 
were calculated over two separate time periods – 1992 to 1998 and 1999 to 2007. The conservative 287 
estimates of the CLBR after three complete cycles increased by almost 40% from the earlier to the 288 
later period (from 30.8% to 42.3%) whilst optimal estimates increased by 30% (from 44.6% to 289 
57.1%). The conservative cumulative multiple pregnancy rate decreased from around 32% in period 290 
1 to 26% in period 2 across all complete cycles. By age group, the CLBR per woman declined from the 291 
age of 31 to 35 years.  There was little difference between the CLBRs across the different types of 292 
infertility with conservative estimates ranging from 39% to 46% from 1999 to 2007.  The log-rank 293 
test was statistically significant for this difference, however, this is almost certainly due to the large 294 
population size.  295 
Strengths and weaknesses of the study 296 
This is the first study to report CLBRs per woman following autologous IVF treatment for the whole 297 
of the UK using national population-based data from 1992 to 2009.  Per woman rates were 298 
estimable because all IVF treatments were linked to the woman, a unique strength for a national IVF 299 
database with a long history of complete treatment capture.  CLBRs were calculated over complete 300 
IVF cycles including fresh and frozen-thawed embryo transfers. This makes the results much more 301 
relevant for clinicians and patients. 302 
Although we were able to link all treatments within women, it was not possible to identify with 303 
certainty from which complete cycle (i.e. episode of ovarian stimulation) each replaced frozen-304 
thawed embryo came.  However, our assumption that any frozen-thawed embryos were most likely 305 
to have been derived from the most recent egg retrieval episode is likely to be correct for all but a 306 
minority of women who may have undergone multiple consecutive fresh transfer attempts and 307 
reserved all frozen embryos for transfer at a later date. In reality, only 14% of all women in our 308 
dataset had a frozen-thawed embryo transfer attempt; thus, CLBRs tended to be dominated by the 309 
outcome of the first fresh treatment. CLBRs could not be calculated for women who started 310 
 treatment in 2008-2009 since the minimum two-year treatment exposure time would have 311 
overlapped the phase, which began in October 2009, when patients had to give formal consent for 312 
their data to be disclosed for research purposes (Human Fertilisation and Embryology Authority 313 
2008b).  314 
Strengths and weaknesses in relation to other studies 315 
The conservative estimate of the CLBR is a pessimistic one since it assumes that women who do not 316 
achieve a live birth do not have any continued chance of getting pregnant – it reflects the observed 317 
treatment specific CLBR.  The optimal estimate is seen as optimistic since it assumes that women 318 
who discontinue without having a live birth still have the same chance of a live birth as those who 319 
continue. This future chance of live birth can be interpreted as either a hypothetical ideal world 320 
scenario where there is no barrier to future treatment (which is only true for some women) or as 321 
one arising from a natural conception (assuming that such chances are similar to those who continue 322 
with IVF).  A ͚ƌealistiĐ͛ estiŵate of the CLBR can be calculated which assumes that women who 323 
discontinue because of a medical indication had no continued chance of achieving a live birth, while 324 
those who stopped treatment for other reasons had the same probability of achieving a live birth 325 
after IVF as those who continued (Stolwijk et al. 2000).  Unfortunately the HFEA database did not 326 
hold the reasons for discontinuation of IVF treatment meaning calculation of the realistic estimate 327 
was not possible.  However, a previous study found that 22.5% of women who failed 2-4 IVF 328 
attempts went on to have a treatment dependent live birth (Troude et al. 2012).  Assuming a similar 329 
rate in our study gives a realistic estimate of approximately 55.3% after three complete cycles which 330 
is just lower than the optimal estimate of 57.1%.  Without knowing the reason for withdrawal it is 331 
possible that the realistic estimate may show lower rates for the later time period compared to the 332 
earlier time period.  For this to happen it would mean that the discontinuation rate due specifically 333 
to medical indication had increased sufficiently enough over time to have the effect of lowering the 334 
 CLBR.  With the lowering of the threshold for IVF treatment this is unlikely to be the case (Kamphuis 335 
et al. 2014).   336 
It is not possible to directly compare the finding from the current study with that from the US since 337 
the latter did not assess the CLBRs over complete cycles of IVF but did so over cumulative fresh or 338 
frozen-thawed treatments (Luke et al. 2012).  Also, the US study period was 2004 to 2008 whilst the 339 
pƌeseŶt studǇ͛s latteƌ tiŵe peƌiod ǁas fƌoŵ ϭ999 to ϮϬϬ7.   340 
In Australia and New Zealand, the overall conservative CLBR after three successive fresh or frozen-341 
thawed embryo transfers was 36.0% which is slightly lower than the UK rate of 39.8% after three 342 
complete cycles (Macaldowie et al. 2013).  However, as for the US, that study examined CLBRs over 343 
cumulative fresh or frozen-thawed treatments rather than complete cycles as in our study.  The 344 
study period was 2009 to 2011 meaning that only those women who began treatment in 2009 345 
ĐoŶtƌiďuted at least tǁo Ǉeaƌs͛ ǁoƌth of tƌeatŵeŶt to the Đuŵulatiǀe ƌates.    346 
Meaning of the study 347 
Our results provide an estimate of the chances of a couple taking a baby home after one or more 348 
complete cycles of IVF.  They also confirm the fact that, despite rising female age, the CLBR in the 349 
U.K. has increased over time while the multiple pregnancy rate has declined.  This reflects 350 
improvements in reproductive technology and the evolution towards a more conservative embryo 351 
transfer policy (McLernon et al. 2010).The multiple pregnancy rate per pregnant woman reduced 352 
from 31.9% in women who commenced IVF during period 1 to 26.2% during period 2 reflecting the 353 
reduction in triple embryo transfers.  The latter rate is slightly lower than that reported in Canada in 354 
2004 of 30% (Health Quality Ontario, 2006) and is actually lower than many countries͛ multiple birth 355 
rate including Guatemala (71.5%), Brazil (55.9%), Argentina (43.1%), Taiwan (40.5%) and USA 356 
(31.5%) (Sullivan et al. 2013).  Since the end of our study period the HFEA have reported that the 357 
multiple pregnancy rate has reduced further to 16.4% in 2013 (Human Fertilisation and Embryology 358 
 Authority 2015) reflecting the strong drive by the HFEA to reduce the multiple pregnancy rate 359 
(Human Fertilisation and Embryology Authority 2013c).  360 
 361 
Elective single embryo transfer (SET) with cryopreservation of surplus embryos can optimise the 362 
safety and success of IVF (NatioŶal CollaďoƌatiŶg CeŶtƌe foƌ WoŵeŶ͛s aŶd ChildƌeŶ͛s Health 2013).  363 
The traditional focus on presenting outcomes per fresh IVF treatment has tended to discourage use 364 
of elective SET which, inevitably, is associated with slightly lower live birth rates per fresh treatment 365 
but comparable cumulative outcomes.  In addition, given the relatively modest success rates of IVF 366 
per fresh/frozen-thawed embryo transfer, commissioners and health planners, as well as patients 367 
who pay for IVF appreciate being able to base their decisions regarding treatment on a realistic 368 
expectation of CLBRs after one or more complete cycles of IVF i.e. a package of fresh (and their 369 
accompanying frozen-thawed) treatments.  370 
Despite NICE recommendations in 2004, most couples in the UK still do not receive three complete 371 
IVF cycles.  The majority of patients discontinue IVF after receiving one complete cycle which may be 372 
due to ǀaƌious ƌeasoŶs iŶĐludiŶg the NatioŶal Health “eƌǀiĐe͛s ƌatioŶiŶg of IVF iŶ diffeƌeŶt ƌegioŶs 373 
(National Institute for Health and Clinical Excellence 2014), a lack of personal funds, psychological 374 
burden of treatment, relationship problems/divorce, physical burden (Lande et al. 2014, Verberg et 375 
al. 2008, Olivius et al. 2004). This was reflected in the conservative CLBRs which stabilised after three 376 
successive complete cycles.  For those women with no barrier to continued treatment, our results 377 
show that the CLBR after eight complete cycles would be 82% (optimal estimate) which is similar to 378 
the live birth rate within two years in 30 to 35 year old women from a simulated natural population 379 
(Leridon 2004).   The per complete cycle live birth rates declined slowly with each successive 380 
complete cycle e.g. a woman starting her second complete cycle of treatment has almost as high a 381 
chance of success as when she started her first.  Our findings offer important reassurance to women 382 
contemplating whether to persist with treatment.  They also add further support to a recent call 383 
 from NICE to end the postcode lottery of IVF treatment and to develop consistent IVF policies on 384 
access to treatment across all clinical commissioning groups (Everywomen 2013).  Our findings for 385 
the optimal CLBR should be reassuring for countries, such as Belgium (Berg Brigham et al. 2013) and 386 
Israel (Lande et al. 2011), who conduct more than the UK͛s maximum of three complete cycles and 387 
where lack of patient funds is not such a potential barrier to treatment.  388 
Unanswered questions and future research 389 
CLBRs per woman over time are useful to inform clinicians, patients and policy makers about the 390 
national improvement in success rates and the overall chances of live birth.  However, there is a 391 
need to provide patients with a more individualised estimate of their chances of live birth over 392 
multiple complete cycles.  Clinical prediction models would allow clinicians to make more informed 393 
treatment decisions tailored to the characteristics of the woman and her treatment.  The recently 394 
released IVFPredict clinical prediction tool can estimate the probability of a live birth for a specific 395 
treatment attempt number (Nelson and Lawlor 2011). However, it cannot estimate the cumulative 396 
chances of a live birth over multiple complete cycles of IVF.   397 
Conclusions 398 
The last two decades have witnessed a rise in CLBRs accompanied by a decline in multiples.  Yet 399 
most UK couples who do not conceive after their first complete cycle do not receive a further two 400 
complete NHS funded IVF cycles as recommended by NICE. If there were no barriers to continuation 401 
of IVF treatment, around 83% of women receiving IVF would achieve a live birth by the eighth 402 
complete cycle, similar to the natural live birth rate in a non-contraception practising population. 403 
These data should be used to inform policy and counsel patients commencing IVF treatment. 404 
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 562 
 Table 1. Characteristics of the couple at the start of their first complete cycle 563 
Characteristics Period, N(%), unless otherwise stated 
1992 to 1998 
N=71551 
1999 to 2007 
N=107347 
Female Age (y), mean (SD) 33.4 (4.5) 34.1 (4.6) 
 <31 19646 (27.5) 23391 (21.8) 
 31 to 35 29260 (40.9) 41459 (38.6) 
 36 to 40 18343 (25.6) 33866 (31.5) 
 >40 4302 (6.0) 8631 (8.0) 
Duration (y), median (IQR) 2 (2 to 4) 4 (3 to 6) 
Type of infertility    
 Unexplained only 31353 (43.8) 29181 (27.2) 
 Tubal only 10716 (15.0) 17634 (16.4) 
 Anovulation only 1115 (1.6) 7425 (6.9) 
 Endometriosis only 965 (1.3) 3591 (3.3) 
 Cervical only 83 (0.1) 47 (0.0) 
 Male factor only 440 (0.6) 33427 (31.1) 
 >1 type of infertility 26879 (37.6) 16042 (14.9) 
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 567 
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 569 
 570 
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 575 
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 580 
 Table 2. Treatment information for women commencing IVF during two time periods 581 
 582 
Treatment information Period, N(%), unless otherwise stated 
1992 to 1998 
N=71551 
1999 to 2007 
N=107347 
First fresh treatment characteristics  
 
IVF 59322 (82.9) 64587 (60.2) 
ICSI 12229 (17.1) 42760 (39.8) 
Number of oocytes, median (IQR) 8 (4, 12) 8 (5, 13) 
Number of embryos created, median (IQR) 4 (1, 7) 5 (2, 8) 
   
Number of embryos transferred   
 0 14349 (20.1) 14831 (13.8) 
 1 5886 (8.2) 9038 (8.4) 
 2 23555 (32.9) 74496 (69.4) 
 3 27761 (38.8) 8982 (8.4) 
Cryopreservation of embryos 15184 (21.2) 27711 (25.8) 
   
Overall treatment information (per woman)   
Number of fresh/frozen treatment attempts 
until end of follow-up1, median (IQR) 
2 (1, 3) 1 (1, 2) 
Number of complete cycles until end of 
follow-up1, median (IQR) 
1 (1, 2) 1 (1, 2) 
Number of couples with at least one frozen 
embryo transfer attempt 
10609 (14.8%) 14979 (14.0%) 
Number of complete cycles until first live 
birth2, median (IQR) 
1 (1, 2) 1 (1, 2) 
Time (days) from first fresh treatment attempt  
to last fresh/frozen treatment attempt, 
median (IQR)3 
365 (185, 701) 314 (165, 609) 
Time (days) from first fresh treatment attempt 
to last fresh/frozen treatment attempt leading 
to live birth2, median (IQR) 
0 (0, 282) 0 (0, 196) 
 583 
1 Follow-up defined as first live birth or end of study (whichever came first) 584 
2 Only includes women who had a live birth 585 
3 Excludes women who only had one fresh treatment attempt i.e. no frozen embryo transfer 586 
attempts or further ovarian stimulations. 587 
 Table 3. Live birth rates per complete cycle and cumulative live birth rates per woman by period 588 
 589 
Period 
Complete 
cycle 
No. 
Women 
No. women 
with at least 
one live birth 
Conditional live 
birth rate 
Conservative 
cumulative live birth 
rate 
Optimal cumulative live 
birth rate 
1992-1998 1 71551 13697 19.1 (18.85, 19.43) 19.1 (18.85, 19.43) 19.1 (18.86, 19.43) 
 2 33155 5960 18.0 (17.56, 18.39) 27.5 (27.15, 27.80) 33.7 (33.27, 34.09) 
 3 14288 2356 16.5 (15.88, 17.10) 30.8 (30.43, 31.10) 44.6 (44.09, 45.145) 
 4 5649 905 16.0 (15.06, 16.98) 32.0 (31.69, 32.37) 53.5 (52.80, 54.18) 
 5 2135 333 15.6 (14.06, 17.14) 32.5 (32.15, 32.84) 60.7 (59.82, 61.67) 
 6 878 117 13.3 (11.08, 15.57) 32.7 (32.32, 33.00) 66.0 (64.78, 67.16) 
 7 372 51 13.7 (10.21, 17.20) 32.7 (32.39, 33.07) 70.6 (69.06, 72.20) 
 8 147 14 9.5 (4.78, 14.27) 32.8 (32.41, 33.09) 73.4 (71.43, 75.41) 
 
1999-2007 
 
1 107347 30546 28.5 (28.19, 28.73) 28.5 (28.19, 28.73) 28.5 (28.19, 28.73) 
 2 46439 11116 23.9 (23.55, 24.32) 38.8 (38.52, 39.10) 45.6 (45.24, 45.93) 
 3 17913 3791 21.2 (20.57, 21.76) 42.3 (42.05, 42.64) 57.1 (56.67, 57.52) 
 4 6253 1189 19.0 (18.04, 19.99) 43.5 (43.15, 43.75) 65.3 (64.71, 65.80) 
 5 2175 365 16.8 (15.21, 18.35) 43.8 (43.49, 44.09) 71.1 (70.38, 71.79) 
 6 793 121 15.3 (12.76, 17.76) 43.9 (43.61, 44.20) 75.5 (74.55, 76.43) 
 7 292 44 15.1 (10.97, 19.17) 43.9 (43.65, 44.24) 79.2 (77.89, 80.46) 
 8 110 17 15.5 (8.70, 22.21) 44.0 (43.66, 44.26) 82.4 (80.59, 84.14) 
 590 
 591 
 592 
 Figure legends 593 
  
Figure 1 Flow chart of exclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial population  
253,417 women with 464,333 
complete cycles (564,224 fresh/frozen 
treatments) Exclusions 
Women who had at least one treatment that 
was not IVF or ICSI (20625 women) 
Women who ever underwent IVF for purposes of 
egg/embryo storage (9724 women) 
Women who had a subsequent fresh treatment 
within 42 days of previous treatment or a frozen 
treatment within 28 days of previous treatment 
(4511 women) 
Women whose first treatment was a frozen 
treatment (4250 women) 
Women who had unusual treatment information 
(coding errors) (834 women) 
Women who at their first treatment were under 
18 years old or over 50 years old (59 women) 
Women who ever had >3 embryos transferred 
(49 women) 
 
218,591 women with 388,552 
complete cycles (438,454 
fresh/frozen treatments between 
1992 and 2011) 
Further exclusions for cumulative live birth rate 
analysis 
Women whose first complete cycle occurs after 
2007 
Treatments occurring after 2009 
Treatments occurring after 2000 in women whose 
first treatment was between 1992 and 1998. 
(39,693 women and 67,668 fresh/frozen 
treatments) 
 
107,347 women whose first 
complete cycle was from 1999 to 
2007 (192557 complete cycles; 
219,765 treatments from 1999 to 
2009) 
71,551 women whose first complete 
cycle was from 1992 to 1998 
(133,519 complete cycles; 151,021 
fresh/frozen treatments from 1992 
to 2000) 
 594 
 Figure 2: (A) Conservative cumulative live birth rates per woman and (B) optimal cumulative live 595 
birth rates per woman over multiple complete cycles of IVF (including ICSI) for women commencing 596 
treatment in 1992 to 1998 or 1999 to 2007 597 
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 Table S1 Term singleton live birth rates per complete cycle and cumulative term singleton live birth rates per woman by period 
 
Period 
Complete 
cycle No. Women 
No. women with at least one term 
singleton live birth 
Conditional term singleton live 
birth rate 
Conservative cumulative term singleton 
live birth rate 
Optimal cumulative term singleton 
live birth rate 
1992-1998 1 71551 7596 10.6 (10.39, 10.84) 10.6 (10.39, 10.84) 10.6 (10.39, 10.84) 
 2 33675 3451 10.2 (9.92, 10.57) 15.4 (15.17, 15.70) 19.8 (19.43, 20.13) 
 3 14642 1430 9.8 (9.29, 10.25) 17.4 (17.16, 17.72) 27.6 (27.11, 28.12) 
 4 5833 553 9.5 (8.73, 10.23) 18.2 (17.93, 18.49) 34.5 (33.77, 35.19) 
 5 2218 217 9.8 (8.55, 11.02) 18.5 (18.23, 18.80) 40.9 (39.86, 41.92) 
 6 923 75 8.1 (6.36, 9.89) 18.6 (18.33, 18.90) 45.7 (44.29, 47.11) 
 7 397 29 7.3 (4.75, 9.86) 18.7 (18.37, 18.94) 49.7 (47.77, 51.58) 
 8 159 12 7.5 (3.44, 11.65) 18.7 (18.39, 18.96) 53.5 (50.76, 56.19) 
 
1999-2007 
 
1 107347 18058 16.8 (16.60, 17.05) 16.8 (16.60, 17.05) 16.8 (16.60, 17.05) 
 2 47505 6973 14.7 (14.36, 15.00) 23.3 (23.06, 23.57) 29.0 (28.71, 29.36) 
 3 18600 2491 13.4 (12.90, 13.88) 25.6 (25.38, 25.90) 38.5 (38.09, 38.99) 
 4 6583 778 11.8 (11.04, 12.60) 26.4 (26.10, 26.63) 45.8 (45.18, 46.42) 
 5 2337 243 10.4 (9.16, 11.64) 26.6 (26.33, 26.85) 51.4 (50.57, 52.31) 
 6 870 89 10.2 (8.22, 12.24) 26.7 (26.41, 26.94) 56.4 (55.16, 57.66) 
 7 318 36 11.3 (7.84, 14.80) 26.7 (26.44, 26.97) 61.3 (59.46, 63.22) 
 8 121 12 9.9 (4.59, 15.24) 26.7 (26.45, 26.98) 65.2 (62.50, 67.83) 
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Figure S1 Conditional live birth rate after the first complete cycle of IVF (including ICSI) by year 2 
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Figure S2   Discontinuation rate by complete cycle number by time period of first IVF treatment 19 
(including ICSI) 20 
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